[go: up one dir, main page]

MX2021011524A - Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. - Google Patents

Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.

Info

Publication number
MX2021011524A
MX2021011524A MX2021011524A MX2021011524A MX2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A
Authority
MX
Mexico
Prior art keywords
prmt5 inhibitors
methods
present disclosure
inhibitors
compounds
Prior art date
Application number
MX2021011524A
Other languages
English (en)
Inventor
Michael D Bartberger
Dennis Slamon
Justin A Hilf
Brian M Stoltz
Corey M Reeves
Martina S Mcdermott
Steven J Wittenberger
Oliver C Loson
Brendan M O''boyle
Neil A O''brien
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of MX2021011524A publication Critical patent/MX2021011524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmulas (I)-(V) y métodos para elaborar los mismos. Los compuestos de la presente descripción son útiles como inhibidores de la actividad de PRMT5 y en métodos para tratar cánceres y otras enfermedades. (ver Fórmula).
MX2021011524A 2019-03-25 2020-03-25 Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. MX2021011524A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823374P 2019-03-25 2019-03-25
US201962874773P 2019-07-16 2019-07-16
PCT/US2020/024654 WO2020198323A1 (en) 2019-03-25 2020-03-25 Prmt5 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2021011524A true MX2021011524A (es) 2021-12-15

Family

ID=72609147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011524A MX2021011524A (es) 2019-03-25 2020-03-25 Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220194949A1 (es)
EP (1) EP3947387B1 (es)
JP (1) JP7609798B2 (es)
KR (1) KR20220023330A (es)
CN (1) CN114127072B (es)
AU (1) AU2020245480A1 (es)
BR (1) BR112021019125A2 (es)
CA (1) CA3134779A1 (es)
IL (2) IL318073A (es)
MX (1) MX2021011524A (es)
SG (1) SG11202110272SA (es)
WO (1) WO2020198323A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
AU2021319201A1 (en) 2020-07-31 2023-02-16 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
TW202321246A (zh) * 2021-07-20 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Prmt5抑制劑
JPWO2023127857A1 (es) * 2021-12-27 2023-07-06

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EA030481B1 (ru) * 2013-03-14 2018-08-31 Эпизим, Инк. Ингибиторы аргининметилтрансферазы и их применения
JP6584521B2 (ja) * 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
WO2017153186A1 (en) * 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN111527099B (zh) * 2017-08-09 2024-03-22 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
BR112020010815A2 (pt) * 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos

Also Published As

Publication number Publication date
EP3947387B1 (en) 2024-10-23
IL286622A (en) 2021-12-01
SG11202110272SA (en) 2021-10-28
CN114127072B (zh) 2024-10-11
BR112021019125A2 (pt) 2021-11-30
KR20220023330A (ko) 2022-03-02
CN114127072A (zh) 2022-03-01
CA3134779A1 (en) 2020-10-01
US20220194949A1 (en) 2022-06-23
WO2020198323A1 (en) 2020-10-01
EP3947387A4 (en) 2022-11-30
IL318073A (en) 2025-02-01
JP2022521818A (ja) 2022-04-12
EP3947387A1 (en) 2022-02-09
AU2020245480A1 (en) 2021-11-11
JP7609798B2 (ja) 2025-01-07

Similar Documents

Publication Publication Date Title
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MX2025003444A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2023013912A (es) Metodos para inhibir ras.
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
MX2022000310A (es) Inhibidores de proteina bcl-2.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
PH12022550130A1 (en) Enzyme inhibitors
PH12021552588A1 (en) Cd73 inhibitors
MY199395A (en) Selective inhibitor of exon 20 insertion mutant egfr
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).